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NEUROLOGICAL DISEASES AND OMEGA 3 FATTY ACIDS
OMEGA-3 MASNE KISELINE U NEUROLOŠKIM BOLESTIMA
Dragan M. Pavlović1, Aleksandra M. Pavlović2,3
Abstract Omega-3 long chain polyunsaturated fatty acids (LC-PUFAs) are essential fatty acids necessary 
for normal cell membrane function, that are deffi  cient in contemporary diet. Th ey have anti-infl ammato-
ry properties and are involved in gene expression, cellular signaling and membrane organization. Omega-3 
LC-PUFAs are involved in stimulaton of blood circulation, increase in the breakdown of fi brin, and also 
may reduce blood pressure, and given in food can signifi cant decrease the thickness of the carotid arteries. 
Supplements with omega-3 fatty acids can help control seizures in pharmacoresistent epilepsy. Higher in-
take of omega-3 PUFAs can lower relative risk of dementia incidence or progression and improve memory 
in healty elderly volunteers. Higher fi sh intake was found to lower risk for multiple sclerosis and arrest its 
progression. Favourable eff ects are also found in Huntington’s disease and headache.
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Sažetak Omega-3 polinezasićene masne kiseline dugih lanaca (LC-PUFAs) su esencijalne masne kiseline 
neophodne za normalno funkcionisanje ćelijske membrane, i koje su u savremenoj ishrani defi cijentne. 
Ove masne kiseline imaju anti-infl amatorna svojstva i uključene su u genske ekspresije, celularnu signal-
izaciju i organizaciju membrane. Omega-3 LC-PUFAs su uključene u stimulaciju cirkulacije, povećanje 
razgradnje fi brin, a takođe mogu da smanje krvni pritisak i date u hrani mogu da značajno smanje de-
bljinu zida karotidnih arterija. Suplementi sa omega-3 masnim kiselinama mogu da pomognu u kontro-
li napada farmakorezistentne epilepsije. Veći unos omega-3 PUFAs može da smanji relativni rizik od de-
mencije ili učestalost napredovanja i da poboljša memoriju zdravih starijih volontera. Pronađeno je da viši 
unos ribe može da smanji rizik za oboljevanje od multiple skleroze i zaustavi njeno napredovanje. Povoljni 
efekti se takođe mogu naći u Hantingtonovoj bolesti i glavoboljama.
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INTRODUCTION
Since the mid-19th Century in the industrial 
world there has been a signifi cant decrease in vi-
tal micronutrients, such as omega-3 polyunsat-
urated fatty acids, and an increase in other fats, 
most notably omega-6 fatty acids compared with 
traditional diets rich in fi sh, wild game and leaves 
(1). Th e modern diet is emphasizing grains, dairy 
products and grain-fed meats with increases in to-
tal fat, saturated fat and linoleic acid (2). Th e in-
crease in the consumption of ω-6 fatty acids and a 
marked reduction in the consumption of ω-3 fat-
ty acids in western societies led to an imbalance 
in the ω-6/ω-3 ratio much diff erent from the 1:1 
ratio of humans in the past (and wild animals of 
past and present times) resulting in ω-6/ω-3 ra-
tios in the range of up to 20-30:1 (3). Th e mod-
ern diet has signifi cant caloric intake of predomi-
nantly fats, above the recommended 30-35% with 
a high proportion of saturated fats (> 10%), rich in 
ω-6 and a low proportion of ω-3 fatty acids.
OMEGA 3 FATTY ACIDS
Omega-3 and omega-6 fatty acids are long-chain 
polyunsaturated fatty acids (LC-PUFAs) present 
in fi sh and plants. Omega-3 LC-PUFAs are com-
prised of 20 or more carbon atoms and three or 
more double bonds (4). Th ese oils are classifi ed 
as omega-3 or omega-6 according to the location 
of the last double bond in relation to the terminal 
methyl end of the molecule. Th e carbon chain has 
the acid (COOH) end and the methyl (CH3) end. 
Th e location of the fi rst double bond is counted 
from the methyl end, known also as the omega 
(ω) or n end. In the omega-6 fatty acids, the fi rst 
double bond is between the 6th and 7th carbon at-
oms and for the omega-3 fatty acids the fi rst dou-
ble bond is between the 3rd and 4th (5). 
Th e parental molecules are α-linolenic acid 
(ALA, 18:3n-3) which is “short-chain” eighteen-
carbon n−3 fatty acid for n-3 fatty acids and lino-
leic acid (LA) among n-6 fatty acids. Th rough a 
process of enzymatic desaturation and elongation 
ALA is converted to LC-PUFA: eicosapentaeno-
ic acid (EPA, 20:5n-3), which may in turn be con-
verted to docosahexaenoic acid (DHA, 22:6n-3) in 
the omega-3 series while the linoleic acid (LNA) 
is converted to arachidonic acid (AA) in the ome-
ga-6 series (6). Th ese fatty acids are metabolized in 
the liver. α-linolenic acid and linoleic acid are es-
sential fatty acids and can only be obtained from 
external sources and can not be synthesized in the 
human organism. Th ese acids are vital for nor-
mal metabolism. Fatty acids in the omega-3 and 
omega-6 series cannot be interconverted. An im-
portant point is that ALA is and essential nutrient 
but EPA and DHA are not effi  ciently produced in 
human organism from ALA, so additional exter-
nal sources of these two LC-PUFA are needed for 
optimal level. Th e family of omega 3 fatty acids is 
made up of 8 components.
Th e total omega-3 fatty acids are associated with 
lower levels of pro-infl ammatory markers (IL-6, 
IL-1ra, tumor necrosis factor-а - TNFa, CRP) and 
higher anti-infl ammatory markers (soluble IL-6r, 
IL-10, transforming growth factor-a - TGFa) (7). 
If both n−3 and n−6 fatty acids are present, they 
will “compete” to be transformed, especially im-
portant for the formation of thromboxane a fac-
tor important for the aggregation of platelets. Th e 
leukotrienes are important in immune/infl amma-
tory-system response involved in etiopathogenesis 
of arthritis, systemic lupus, asthma and recovery 
from infections. 
Fatty acids released from membrane phospholip-
ids by cellular phospholipases, or those from the 
diet are important cell signaling molecules acting 
as second messengers of the inositide phospholip-
id and the cyclic AMP signal transduction path-
ways (8). Fatty acids also rapidly and directly alter 
the transcription of specifi c genes involved in in-
fl ammation (9). 
EPA and DHA participate in diverse biologic ac-
tivities thought to be benefi cial to human health. 
It is supposed that majority of positive eff ects of 
omega-3 oils is dependent on immune-modulat-
ing activities, via the mechanisms of gene expres-
sion, cellular signaling and membrane organiza-
tion   (10). Th e omega-3 and omega-6 LC-PU-
FA are precursors of eicosanoids, such as prosta-
glandins, leukotrienes, isoprostanes, lipoxins and 
thromboxanes (11). 
Dietary DHA is incorporated into cell membranes 
resulting in increased fl uidity and permeability af-
fecting cellular signaling determining the binding 
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or release of neurotransmitters (12). Omega-3 fat-
ty acids also have pro- and anti-apoptotic features, 
depending on the tissue. Antiapoptotic properties 
of  DHA metabolites are documented in human 
retinal pigment epithelial cells (13). On the other 
end, in several neoplastic disorders, DHA may ex-
ert antineoplastic properties by promoting tumor 
cell apoptosis (13). 
Th e polyunsaturated fatty acid content changes 
fl uidity inside the membranes-pacemaker mak-
ing possible the activities of membrane-bound en-
zymes, receptors, transporters and other catalytic 
molecules. DHA in neuronal membranes enhanc-
es synaptic membrane fl uidity and function, and 
is involved in regulation of gene expression, cell 
signaling, and in the electrical basis for memory 
formation (14). 
Th e DHA and EPA content of cell membranes de-
pends on current dietary intakes. Within the cell 
membrane, there is a dynamic mechanism of the 
fatty acids attached to phospholipids that are con-
stantly being fi ne tuned by enzymes (acyltrans-
ferases) that remove DHA and EPA from the tails 
of certain phospholipids and reposition them to 
others (15). 
OMEGA 3 FATTY ACIDS IN NEUROLOGI-
CAL DISEASES
Vascular diseases
Chronic infl ammation has been found to con-
tribute in development of cardiovascular disease, 
stroke, and rheumatoid arthritis (16). LC-PU-
FA may stimulate blood circulation, increase the 
breakdown of fi brin, and may reduce blood pres-
sure. One of the possible mechanisms of vascular 
protection is antidiabetic aff ect of EPA and DHA, 
but mostly of ALA maybe through improving in-
sulin sensitivity (17).
It was shown that patients with unhealthy blood 
sugar levels given the EPA had a statistically sig-
nifi cant decrease in the thickness of the carotid ar-
teries, along with improvement in blood fl ow (18). 
A large study confi rmed that fi ve years of receiving 
EPA compared to statin drug showed that patients 
in EPA group had better cardiovascular function 
with reduction of nonfatal coronary events (19).
Another important issue is the ω-6/ω-3 ratio, as 
its good balance is important for the prevention 
and treatment of cardiovascular diseases (1). For 
the secondary prevention of cardiovascular dis-
ease, a ratio of 4:1 has been associated with a 70% 
reduction in total mortality. Th e optimum ratio 
was determined as 4:1-5:1 without exceeding 10:1 
(20). In the view of other negative studies of ra-
tio importance, it has been recommended that hu-
mans has to increase the intake of both ω-6 and 
ω-3 (more so) on daily basis as current foods are 
defi cient in both (21).
Epilepsy
In spite of prolifi c development of new antiepi-
leptic drugs still 20-30% patients are drug resis-
tant and continue to have seizures frequently and 
1 in 1000 patients with chronic epilepsy will die 
with no apparent reason the so called  sudden un-
explained death in epilepsy (SUDEP)  (22). Th ere 
are some evidence from experimental and clinical 
studies that omega-3 fatty acids can control their 
seizures and hence SUDEP. Th e safe ty of omega-3 
supplementation in people with epilepsy has been 
proven (23).
PUFAs are main constituents of mem brane phos-
pholipids in brain tissue playing important roles 
in sleep in duction, long term potentiation, spatial 
learning, syn aptic plasticity, resolution of infl am-
mation and neuroprotection (24). 
Chronic treatment with omega-3 supports neu-
roprotection and positive plastic changes in the 
brain of rats with epilepsy, with a reduction in 
neuro nal death in CA1 and CA3 areas of the hip-
pocampus which could be attributed to n-3 PU-
FAs ion channel mod ulation, and anti-infl amma-
tory action while in in vitro studies DHA showed 
inhib ition of epileptiform activity and synaptic 
transmission mainly through the frequency-de-
pendent blockade of Na+ chan nels in the rat hip-
pocampus, and stabilizing neuronal membrane by 
suppressing voltage-gated Ca2+ currents and Na+ 
channels (22).
Dementia and cognitive decline
Even in healthy subjects DHA and EPA can im-
prove cognitive performance. In a study among 
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volunteers ages 22-51 years consuming either 4 
g fi sh oil/day (providing 800 mg DHA and 1,600 
mg EPA) or 4 g olive oil as placebo, the DHA/EPA 
group improved signifi cantly over placebo on: vig-
or, anger, anxiety, fatigue, depression, confusion, 
reaction time, sustained attention and a signifi -
cant reduction in errors on the attention test (25). 
A small study was done of phophatidylserine-con-
taining omega-3 daily supplementation in eight 
elderly volunteers with subjective memory com-
plaints. Th is supplementation resulted in 42% in-
crease in delayed recall of words (26).
Recent epidemiological studies revealed a positive 
correlation between relatively high DHA and EPA 
intake and lower relative risk of dementia inci-
dence or progression. In the Rotterdam Study fi sh 
consumption was inversely related to dementia in-
cidence and more specifi cally to the risk of devel-
oping Alzheimer’s disease (27). Th e Zutphen El-
derly Study, demonstrated that fi sh consumption 
was inversely associated with cognitive impair-
ment at baseline, and aft er three years, as with the 
Rotterdam study, high fi sh consumption was in-
versely associated with cognitive decline but ome-
ga-3 intake did not correlate with either measure 
(28). Aft er six years, Rotterdam Study data con-
cluded that low intake of omega-3 fatty acids was 
not associated with increased risk for dementia 
(29) while the analysis aft er fi ve years of the Zut-
phen Elderly Study data confi rmed that consum-
ers of fi sh had a statistically signifi cant decrease in 
cognitive decline with higher the intake of DHA/
EPA (an average of 400 mg fi sh omega-3s per day) 
being connected to this eff ect (30). In a Chicago 
community study, residents ages 65-94 were eval-
uated via a self-reported food questionnaire and 
tracked for an average 3.9 years (31). Th ose who 
consumed a fi sh meal once weekly had a statisti-
cally signifi cant 60-percent decreased risk of Al-
zheimer’s disease, compared with those who rare-
ly or never ate fi sh.
As part of the U.S. Framingham Heart Study, a 
subcohort of elderly subjects who were free of de-
mentia at baseline, were followed for a mean 9.1 
years for development of all-cause dementia and 
Alzheimer’s disease (32). Aft er controlling for oth-
er variables, subjects in the upper quartile of plas-
ma phospholipid fraction DHA levels (mean DHA 
intake of 180 mg/day and a mean fi sh intake of 3.0 
servings per week) had approximately half the rel-
ative risk of developing all-cause dementia com-
pared to subjects in the three lower quartiles. 
Many characteristics of n-3 fatty acids make them 
an interesting agent in treating Alzheimer’s dis-
ease (33). Studies done till now are not encourag-
ing. Dietary intake of n-3 fatty acids did not dif-
fer among demented and nondemented subjects 
(34). Some cognitive benefi ts (learning and mem-
ory) were found in very mild cognitive impair-
ment subjects treated with DHA of algal origin, 
but not in mild to moderate Alzheimer’s disease 
(35). More research is needed in omega 3 fatty ac-
ids infl uence on prevention and treatment of de-
mentia. 
In the Atherosclerosis Risk in Communities Study 
older middle aged participants were longitudinally 
followed up and repeatedly tested for word recall, 
psychomotor speed and verbal fl uency (36). High-
er plasma omega-3 fatty acids levels were linked 
to reduced risk for deterioration in verbal fl uen-
cy, particularly in subjects with dyslipidemias and 
hypertension. It was found that the brains of Al-
zheimer’s disease patients have less DHA in the 
gray matter than individuals without Alzheimer’s 
disease at autopsy (37). Individuals with mild cog-
nitive impairment have abnormally low blood lev-
els of DHA and EPA (38).
In a double-blind randomized controlled trial, 
patients with mild-to-moderate Alzheimer’s dis-
ease receiving DHA and EPA daily or a placebo 
for six months, and aft er that the DHA/EPA sup-
plements for six more months, decline in cogni-
tive function did not diff er between groups, but 
in a subgroup with less severe cognitive dysfunc-
tion a signifi cantly slower decline was observed in 
the DHA/EPA group (39). A similar positive eff ect 
was noticed in the placebo group aft er crossover 
to DHA/EPA for the second six months. Th e same 
group reported signifi cant improvement of agita-
tion in apolipoprotein E4 (APOE4) carriers and 
improvement of depression in non-APOE4 carri-
ers on omega-3 supplementation (40).
Multiple sclerosis
Coastal Norwegian residents with higher fi sh and 
less animal fat intake had lowered risk for multiple 
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sclerosis in the study of Swank and collaborators 
(41). Patients instructed to limit animal fat con-
sumption and supplement with cod liver oil (5 g/
day) and have three fi sh meals per week, over 35 
years, experienced a much lower rate of progres-
sion to advanced MS and lower death rate than 
control subjects (42). Also, patients on the re-
stricted diet in early disease, prior to developing 
disability, 95 percent had not progressed.
Huntington’s disease
A purifi ed EPA in its ethyl ester form (“ethyl-
EPA”) in a small randomized controlled trial with 
advanced Hungtington’ disease showed improve-
ment of the orofacial dyskinesia and less brain at-
rophy over  placebo and in a larger study a sus-
picion was raised that it is a mixture of EPA and 
DHA, and not a purifi ed EPA, that might have 
been more eff ective (43).
Headache
High intakes of n-6 PUFAs, LA and AA may pro-
voke physical pain increasing their metabolism 
in immune and nervous tissue, making it a pos-
sible mechanism of chronic daily headache (44). 
AA can directly potentiate N-methyl-d-aspartate 
(NMDA) receptor currents as well as being the 
precursor of various neuroactive and vasoactive 
compounds that are relevant to pain processing. 
Increased omega-3 dietary intake is a possible ad-
juvant factor in treating this type of headache but 
it waits confi rmation from clinical studies.
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